Study summary

Durvalumab after chemoradiation extended survival in limited-stage disease

ADRIATIC trial · Phase 3, double-blind · Published September 2024, New England Journal of Medicine

55.9 momedian survival with durvalumab, vs 33.4 with placebo

What was tested

Durvalumab against placebo after chemoradiation for limited-stage small cell lung cancer.

What they found

Median survival was 55.9 vs 33.4 months.
Time before growth was also longer.

What it means

Now standard after chemoradiation for limited-stage disease.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.